Published in J Clin Invest on June 01, 2004
Phospholipid scramblase 1 is secreted by a lipid raft-dependent pathway and interacts with the extracellular matrix protein 1 in the dermal epidermal junction zone of human skin. J Biol Chem (2010) 0.88
Interaction between cartilage oligomeric matrix protein and extracellular matrix protein 1 mediates endochondral bone growth. Matrix Biol (2010) 0.84
The co-occurrence of lichen sclerosus et atrophicus and celiac disease. Indian Dermatol Online J (2014) 0.81
Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. Oncotarget (2016) 0.76
Unusual remodeling of the hyalinization band in vulval lichen sclerosus by type V collagen and ECM 1 protein. Clinics (Sao Paulo) (2015) 0.75
Pediatric Lichen Sclerosus: A Review of the Literature and Management Recommendations. J Clin Aesthet Dermatol (2016) 0.75
Evaluation of Symptoms and Prevention of Cancer in Menopause: The Value of Vulvar Exam. Transl Med UniSa (2016) 0.75
Lichen sclerosus. J Am Acad Dermatol (1995) 2.84
Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet (2002) 2.41
Lichen sclerosus. Lancet (1999) 2.33
Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol (1997) 2.31
A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest (1993) 2.19
Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc (1971) 2.16
Lichen sclerosus et atrophicus and autoimmunity--a study of 350 women. Br J Dermatol (1988) 1.54
Lipoid proteinosis. Clin Exp Dermatol (2002) 1.53
An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus and atrophicus. Br J Dermatol (1981) 1.44
Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol (1998) 1.41
Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet (2003) 1.39
The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization. Genomics (1997) 1.38
Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem (2003) 1.31
Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol (1998) 1.31
Lichen sclerosus. Clin Exp Dermatol (2003) 1.31
Guidelines for the management of lichen sclerosus. Br J Dermatol (2002) 1.31
Broken dogma: penetration of autoantibodies into living cells. Immunol Today (1996) 1.30
Vulvar lichen sclerosus : pathophysiology and treatment. Am J Clin Dermatol (2004) 1.25
Lichen sclerosus premenarche: autoimmunity and immunogenetics. Br J Dermatol (2000) 1.14
The use of human skin for the detection of anti-epithelial autoantibodies. A diagnostic and prognostic test. J Invest Dermatol (1969) 1.11
The role of extracellular matrix protein 1 in human skin. Clin Exp Dermatol (2004) 1.03
In vitro study of the binding of antiribonucleoprotein antibodies to the nucleus of isolated living keratinocytes. J Invest Dermatol (1981) 0.97
Characterization of IgG autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Clin Exp Dermatol (2004) 0.94
Penetration of autoantibodies into living epithelial cells. J Invest Dermatol (1993) 0.92
Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease. Br J Dermatol (1999) 0.90
The IgE and IgG subclass antibody response to foods in babies during the first year of life and their relationship to feeding regimen and the development of food allergy. J Allergy Clin Immunol (1991) 0.89
Surgical treatment of balanitis xerotica obliterans. Plast Reconstr Surg (1984) 0.88
Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Arch Dermatol (1995) 0.86
Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J Am Acad Dermatol (1994) 0.83
Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med (1995) 0.83
Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol (1996) 0.82
An appraisal of routine direct immunofluorescence in vulvar disorders. Acta Derm Venereol (1981) 0.81
Management of anogenital lichen sclerosus. Clin Exp Dermatol (2001) 0.78
Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity (2010) 5.43
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol (2008) 3.72
Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2008) 3.34
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet (2005) 3.03
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet (2003) 2.73
The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol (2006) 2.62
Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet (2002) 2.41
Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet (2010) 2.38
Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry (2010) 2.35
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp Dermatol (2007) 1.98
Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. J Invest Dermatol (2004) 1.95
Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet (2003) 1.94
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) (2010) 1.83
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74
Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. J Invest Dermatol (2003) 1.67
The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat (2011) 1.65
The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol (2008) 1.64
Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2010) 1.60
Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus Sanguinis antigen. J Invest Dermatol (2006) 1.59
Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol (2010) 1.58
Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol (2007) 1.57
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum (2006) 1.56
HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa. J Invest Dermatol (2011) 1.54
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) (2009) 1.52
Revertant mosaicism in Kindler syndrome. J Invest Dermatol (2011) 1.47
Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa. Acta Derm Venereol (2011) 1.46
A frameshift mutation of the ED1 gene in sibling cases with X-linked hypohidrotic ectodermal dysplasia. Dermatology (2003) 1.42
Multicentric Castleman's disease associated with inherited epidermolysis bullosa. J Dermatol (2003) 1.41
Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet (2003) 1.40
A systematic review of treatments for bullous pemphigoid. Arch Dermatol (2002) 1.40
Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet (2003) 1.39
PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A (2011) 1.38
Genetic diseases of junctions. J Invest Dermatol (2007) 1.38
Pyoderma gangrenosum following surgical procedures. Int J Dermatol (2010) 1.38
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One (2013) 1.32
Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet (2004) 1.29
Fine mapping on chromosome 10q22-q23 implicates Neuregulin 3 in schizophrenia. Am J Hum Genet (2009) 1.27
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev (2011) 1.27
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. Am J Hum Genet (2006) 1.21
Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord (2010) 1.19
LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol (2005) 1.19
Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol (2002) 1.19
RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet (2012) 1.18
Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging (2013) 1.16
Lack of plakophilin 1 increases keratinocyte migration and reduces desmosome stability. J Cell Sci (2003) 1.16
Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol (2010) 1.16
Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol (2002) 1.15
Diseases of epidermal keratins and their linker proteins. Exp Cell Res (2007) 1.13
Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13
Primary Wegener's granulomatosis of the orbital apex with initial optic nerve infiltration. Orbit (2011) 1.13
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12
Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res (2011) 1.11
Kindler syndrome. Dermatol Clin (2010) 1.11
The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol (2010) 1.10
Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet (2008) 1.10
Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) (2008) 1.10
The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study. Trials (2012) 1.10
Molecular basis of Kindler syndrome in Italy: novel and recurrent Alu/Alu recombination, splice site, nonsense, and frameshift mutations in the KIND1 gene. J Invest Dermatol (2006) 1.10
Interventions for bullous pemphigoid. Cochrane Database Syst Rev (2010) 1.09
Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. Nat Genet (2012) 1.08
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res (2012) 1.07
Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol (2006) 1.07
A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol (2009) 1.06
Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA (2009) 1.05
A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease. J Invest Dermatol (2006) 1.04
Progress in Epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Invest Dermatol (2013) 1.04
Alterations in desmosome size and number coincide with the loss of keratinocyte cohesion in skin with homozygous and heterozygous defects in the desmosomal protein plakophilin 1. J Invest Dermatol (2003) 1.04
Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol (2002) 1.03
Novel molecular therapies for heritable skin disorders. J Invest Dermatol (2011) 1.03
Revertant mosaicism in skin: natural gene therapy. Trends Mol Med (2010) 1.03
Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol (2003) 1.02
A novel translation re-initiation mechanism for the p63 gene revealed by amino-terminal truncating mutations in Rapp-Hodgkin/Hay-Wells-like syndromes. Hum Mol Genet (2008) 1.02
Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed. PLoS One (2012) 1.02
Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci (2009) 1.01